Patents Assigned to Seragen, Inc.
-
Patent number: 6074636Abstract: The invention features a method for treating a patient infected with a virus. The method includes administering to the patient a molecule which is capable of specifically binding to a proteinaceous cell receptor expressed on a cell of the patient which cell contributes to the disease state of the patient, the molecule being capable of decreasing the viability of the cell.Type: GrantFiled: June 5, 1995Date of Patent: June 13, 2000Assignee: Seragen, Inc.Inventor: Jean C. Nichols
-
Patent number: 6022950Abstract: Disclosed is a hybrid molecule comprising a first part, a second part, and a third part connected by covalent bonds,(a) wherein said first part comprises a portion of the binding domain of a cell-binding polypeptide ligand effective to cause said hybrid protein to bind to a cell of an animal;(b) wherein said second part comprises a portion of a translocation domain of naturally occurring protein which translocates said third part across the cytoplasmic membrane into the cytosol of the cell; and(c) wherein said third part comprises a chemical entity to be introduced into the cell, wherein each of said first part and said third part is non-native with respect to said naturally occurring protein, and further wherein said covalent bond connecting said second part and said third part is a cleavable bond, provided that when said second part comprises a portion of a translocation domain of Pseudomonas exotoxin, said third part is not a polypeptide.Type: GrantFiled: June 7, 1995Date of Patent: February 8, 2000Assignee: Seragen, Inc.Inventor: John R. Murphy
-
Patent number: 5965406Abstract: Disclosed is a recombinant DNA molecule encoding a hybrid protein comprising a first part, a second part, and a third part,(a) wherein said first part comprises a portion of the binding domain of a cell-binding polypeptide ligand effective to cause said hybrid protein to bind to a cell of an animal;(b) wherein said second part comprises a portion of a translocation domain of naturally occurring protein selected from the group consisting of diphtheria toxin, botulinum neurotoxin, ricin, cholera toxin, LT toxin, C3 toxin, Shiga toxin, Shiga-like toxin, pertussis toxin and tetanus toxin, which translocates said third part across the cytoplasmic membrane into the cytosol of the cell; and(c) wherein said third part comprises a polypeptide entity to be introduced into the cell, wherein said third part is non-native with respect to said naturally occurring protein of (b).Type: GrantFiled: June 7, 1995Date of Patent: October 12, 1999Assignee: Seragen, Inc.Inventor: John R. Murphy
-
Patent number: 5906820Abstract: The invention features a method for treating a patient having inflammatory arthritis, the method includes administering to the patient a molecule which is capable of specifically binding to an epidermal growth factor receptor expressed on a cell of the patient which contributes to the inflammatory arthritis of the patient, the molecule being capable of decreasing the viability of the cell.Type: GrantFiled: May 5, 1997Date of Patent: May 25, 1999Assignee: Seragen, Inc.Inventor: Patricia A. Bacha
-
Patent number: 5684221Abstract: A method for producing a mouse having a systemic malignant disease which mimics a human IL-2 expressing. T-cell malignancy, which includes administering to a mouse a mixture of passaged cells comprising cancer causing cells, the mixture having been rendered cancer causing by in vivo passage of tumor inducing cells in athymic mice.Type: GrantFiled: May 12, 1994Date of Patent: November 4, 1997Assignee: Seragen, Inc.Inventors: Serene E. Forte, Patricia Bacha
-
Patent number: 5668255Abstract: A hybrid molecule including a first part and a second part connected by a covalent bond,(a) the first part including a portion of the binding domain of a cell-binding ligand, which portion is able to cause the hybrid molecule of the invention to bind to an animal cell; and(b) the second part including a portion of a translocation domain of a protein, provided that (i) the hybrid molecule does not include an enzymatically-active portion of the protein, (ii) the first part and the second part are not segments of the same naturally-occurring polypeptide toxin, and (iii) the portion of the translocation domain, when covalently bonded to the enzymatically-active effector region of a toxin selected from diphtheria toxin, Pseudomonas exotoxin A, cholera toxin, ricin toxin, and Shiga-like toxin, is capable of translocating such effector region across the cytoplasmic membrane of the cell.Type: GrantFiled: August 4, 1993Date of Patent: September 16, 1997Assignee: Seragen, Inc.Inventor: John R. Murphy
-
Patent number: 5614488Abstract: The invention features a method for treating a patient having inflammatory arthritis, the method includes administering to the patient a molecule which is capable of specifically binding to an epidermal growth factor receptor expressed on a cell of the patient which contributes to the inflammatory arthritis of the patient, the molecule being capable of decreasing the viability of the cell.Type: GrantFiled: September 3, 1993Date of Patent: March 25, 1997Assignee: Seragen, Inc.Inventor: Patricia A. Bacha
-
Patent number: 5571507Abstract: A method of treating a patient with diabetes involving administering to the patient a hybrid molecule which contains a cytotoxin covalently joined to interleukin-2 which is capable of binding to interleukin-2 receptor on a cell that contributes to the disease state of the cell and decreasing the viability of that cell.Type: GrantFiled: February 25, 1992Date of Patent: November 5, 1996Assignee: Seragen, Inc.Inventors: Vicki E. Rubin-Kelley, Terry B. Strom, Jean-Francois Bach, Jean C. Nichols
-
Patent number: 5110912Abstract: A method for purifying from a mixture of hybrid compound which contains a portion of IL-2, which portion includes at least a region of the IL-2R binding domain of IL-2, which region is effective to cause the hybrid compound to bind to cells containing an IL-2R. The method includes passing the mixture containing the hybrid compound over a column having attached thereto molecules consisting of or containing a complex sugar moiety with affinity for the hybrid compound, and eluting the hybrid compound with a suitable eluant. The invention also features related complexes of the hybrid compound and assays for the hybrid compound.Type: GrantFiled: March 2, 1990Date of Patent: May 5, 1992Assignee: Seragen, Inc.Inventor: Leonard F. Estis